Analyst firms · H.C. Wainwright · XERS

H.C. Wainwright XERS price target and rating history

Xeris Biopharma Holdings Inc. (XERS) · Health Care

H.C. Wainwright rates Xeris Biopharma Holdings Inc. (XERS) Buy with a $10 price target, as of its latest action on Aug 12, 2025. It has published 3 rating actions on XERS since October 2021, including 0 upgrades and 0 downgrades.

Current rating
Buy
Price target
$10
Median target, all firms
Too few
Actions on XERS
3

H.C. Wainwright price target on XERS

$10$7$420222023202420252026
H.C. Wainwright price target on XERS, each point a stated target, October 2021 to August 2025.

Every H.C. Wainwright rating on XERS

Questions about H.C. Wainwright and XERS

What is H.C. Wainwright's price target for XERS?
H.C. Wainwright's latest stated price target for Xeris Biopharma Holdings Inc. (XERS) is $10, from its action on Aug 12, 2025.
What is H.C. Wainwright's rating on XERS?
H.C. Wainwright rates XERS Buy, a bullish rating, as of Aug 12, 2025.
When did H.C. Wainwright last change its view on XERS?
On Aug 12, 2025, H.C. Wainwright resumes coverage at Buy, price target $10.

More XERS rating histories

All H.C. Wainwright ratingsXERS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.